Company history

Chugai began as a way into a market without the cost of entering it. After the 1923 Great Kanto Earthquake, Ueno Juzo, then working at a trading firm, concluded that demand for medicines would not fade, and in March 1925 set up Chugai Shinyaku Shokai as a sole proprietorship importing drugs as agent for the German house Gehe — no plant, no research, no risk beyond the contract. In 1927 he built a factory in Ikebukuro and began making the injectable Zarusoburokanon, turning an import agency into a manufacturer. Ueno described his own method as “all-in on Zarublo”: concentrate everything on a few products and compete on making and selling them well rather than on widening the range.

That model carried the company through a new plant at Takada in 1936 and incorporation in 1943, and it survived the war intact — but it rested on a structural gap. Chugai manufactured without a research base of its own, and Ueno said as much: the drugs he could make were the ones for the heart and the liver, and no more. After 1945 the gap was filled from outside rather than inside. Professor Ishidate Morizo of the University of Tokyo had worked on glucuronic acid; Chugai patented the process in 1950 and launched the detoxicant Gronsan as an injection in 1951. When the board balked at scaling to a tonne a month, Ueno forced it through by offering his own house and land as collateral against failure. A 1954 synthesis route from starch and dilute nitric acid took Gronsan out of the clinic and into the pharmacy as a consumer tonic.

The concentration that built the company then broke it. Gronsan became the revenue pillar, which meant the pillar’s bad years were the company’s bad years. Tanabe’s rival Aspara ran ahead in 1965 while Chugai’s counterattack, Orpa, went nowhere; consumer distrust of tonic drugs and the cold-remedy scandal cut pharmacy sales further, and the Chugai-kai dealer network created in 1964 could not hold the line. In the year ended March 1966 the company passed its dividend and solicited 420 early retirements. Licensing other people’s science, it turned out, could not widen the product range fast enough to absorb a single product’s bad year.

The dividendless year forced the conclusion that the next pillar had to be grown rather than licensed. The Comprehensive Research Laboratory opened in Takada in 1960 became the base for it, and in February 1971 Chugai entered clinical diagnostics with blood analysers and reagents — the first deliberate widening of a portfolio that had been one product deep for four decades.

The larger commitment began in the mid-1970s with Neutrogin, a recombinant protein that raises white-blood-cell counts. Its molecule was tens of times the size of a small-molecule drug, no manufacturing route existed, and the industry as a whole could not say when — or whether — biotechnology would pay. In the early 1980s president Ueno Kimio and R&D director Sano Hajime decided to keep funding it anyway. Clinical trials began in 1987 and the drug reached market in 1991, sixteen-odd years after the work started. Nagayama Osamu later put it plainly: without that decision there would be no Chugai today. The memory of 1966 is what made an open-ended bet defensible — a company that had already been broken by a narrow product base could justify a long, undated investment in a wide new one.

What the sixteen years bought was not one drug but a resident capability in recombinant engineering and manufacture, and that capability fed directly into the antibody programme that entered the clinic in the late 1990s. It also exposed the other half of the equation. Chugai took an equity stake in Genetics Institute in 1984 to secure rights to the blood hormone EPO, and in 1987 Amgen sued it over EPO patents — a fight decided as much by litigation budget and negotiating weight as by science. A mid-sized Japanese firm could invent biologics; it could not by itself carry a late-stage trial costing tens of billions of yen per compound, nor build the overseas sales network to sell the result.

Nagayama Osamu became president in 1992 and made biologics the company’s stated axis. The build-out continued — a US subsidiary in 1995, European entities through the decade, a new research institute at Tsukuba in 2001 — but the arithmetic worsened as it went. Every additional compound in the antibody pipeline implied a late-stage trial Chugai could not fund alone and a global launch it had no channel to execute.

The industry’s own restructuring made the gap explicit. By 2000 the price of survival was being quoted as $10 billion in sales and $2 billion in R&D a year, and a wave of cross-border mergers was setting that bar. Chugai had the rarer asset — genuine discovery capability in antibodies — and lacked the commoner one, scale. Add the looming 2004 patent expiry on Epogin, its anaemia mainstay, and the decade resolved into a single question: build a global sales organisation it could not afford, or specialise in discovery and hand late development and overseas selling to someone who already had them. Nagayama’s first ten years were, in effect, spent narrowing to that choice.

In October 2002 Chugai formed a strategic alliance with Roche of Switzerland. Roche took a majority through a tender offer and a third-party allotment, holding 50.13% as of the end of March 2003; Chugai merged with Nippon Roche and took over selling Roche products in Japan. What made the deal unusual was what Chugai kept. It stayed listed, kept its name and kept its own management, and it retained discovery and early development in-house while late-stage trials and all overseas commercialisation went to Roche’s network. The bargaining power to set those terms came from the antibody platform built since Neutrogin: Roche was buying capability, not rescuing a balance sheet. Nagayama, who described the size gap as a rank-and-file wrestler against a grand champion, has said he had no certainty at the time that it would work.

Specialising meant subtracting. Chugai spun off Gen-Probe and sold Chugai Diagnostics Science to Fujirebio in September 2002; closed the Takada laboratory and the Matsunaga plant in 2003; sold the over-the-counter business — the direct descendant of Gronsan, and of the founder’s all-in method — to Lion in December 2004; closed the three-year-old Tsukuba institute in 2005; and sold the Kagamiishi plant and Tohoku Chugai to Nipro the same year. The consumer lineage that had made the company was disposed of so that the prescription antibody business could have the resources.

The pipeline justified the subtraction. Actemra, Japan’s first domestically discovered antibody drug, launched in 2005 and reached the world through Roche’s channels; the haemophilia A antibody Hemlibra (emicizumab) followed, and revenue and profit have compounded since. The footprint was then rearranged to match: an antibody discovery subsidiary in Singapore in 2012, a Chinese venture in 2014 and a merged Chinese development-and-sales organisation in 2022, while in Japan the Fuji-Gotemba and Kamakura laboratories closed in March 2023 and research consolidated into the Chugai Life Science Park Yokohama the following month. With late development delegated, speed in discovery is the only competitive variable left, and Okuda Osamu — president since 2020 — has aimed the TOP I 2030 growth plan at mid-size molecules and AI-led drug discovery on that single site.